成人斯蒂尔病：从病理生理学到靶向治疗
Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.
作者信息
Mavragani Clio P, Spyridakis Evangelos G, Koutsilieris Michael
机构信息
Department of Experimental Physiology, School of Medicine, University of Athens, Athens 11527, Greece.
出版信息
Int J Inflam. 2012;2012:879020. doi: 10.1155/2012/879020. Epub 2012 Jun 26.
Abstract
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder affecting primarily young individuals. The diagnosis is primarily clinical and necessitates the exclusion of a wide range of mimicking disorders. Given the lack of solid data in regard to the underlying pathogenetic mechanisms, treatment of AOSD has been for years largely empirical. Recent advances have revealed a pivotal role of several proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-18 (IL-18) in disease pathogenesis, giving rise to the development of new targeted therapies aiming at optimal disease control.
摘要
成人斯蒂尔病（AOSD）是一种主要影响年轻人的全身性炎症性疾病。诊断主要依靠临床症状，且需要排除多种相似疾病。鉴于缺乏关于潜在发病机制的确切数据，多年来AOSD的治疗很大程度上都是经验性的。最近的研究进展揭示了几种促炎细胞因子，如肿瘤坏死因子-α（TNF-α）、白细胞介素-1（IL-1）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）和白细胞介素-18（IL-18）在疾病发病机制中起关键作用，从而推动了旨在实现最佳疾病控制的新型靶向治疗方法的发展。
相似文献
1
Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.
Int J Inflam. 2012;2012:879020. doi: 10.1155/2012/879020. Epub 2012 Jun 26.
2
Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.
Ann Med. 2015 Feb;47(1):6-14. doi: 10.3109/07853890.2014.971052. Epub 2015 Jan 22.
3
Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.
Drugs. 2018 Aug;78(12):1187-1195. doi: 10.1007/s40265-018-0956-9.
4
Pathogenesis and management of adult-onset Still's disease.
Semin Arthritis Rheum. 2006 Dec;36(3):144-52. doi: 10.1016/j.semarthrit.2006.07.001. Epub 2006 Sep 1.
5
Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Semin Arthritis Rheum. 2021 Aug;51(4):858-874. doi: 10.1016/j.semarthrit.2021.06.004. Epub 2021 Jun 13.
6
Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity.
Arthritis Res Ther. 2018 Mar 22;20(1):54. doi: 10.1186/s13075-018-1555-6.
7
AIM2 and NLRC4-driven inflammasome activation in adult-onset Still's disease and the preliminary therapeutic effect exploration of carboxyamidotriazole.
Clin Rheumatol. 2023 Jun;42(6):1635-1643. doi: 10.1007/s10067-022-06443-1. Epub 2022 Nov 24.
8
Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
J Rheumatol. 2004 Nov;31(11):2189-98.
9
Adult-onset Still's disease: Advances in the treatment.
Best Pract Res Clin Rheumatol. 2016 Apr;30(2):222-238. doi: 10.1016/j.berh.2016.08.003. Epub 2016 Oct 5.
10
Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Nat Clin Pract Rheumatol. 2007 Jun;3(6):328-35. doi: 10.1038/ncprheum0510.
引用本文的文献
1
Autoimmune rheumatic transitional care model development.
BMC Rheumatol. 2024 Aug 29;8(1):38. doi: 10.1186/s41927-024-00407-5.
2
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option.
Cells. 2023 Jun 2;12(11):1534. doi: 10.3390/cells12111534.
3
The Great Still-Usion: Unmasking Adult-Onset Still's Disease Masquerading As Upper Respiratory Tract Infection.
Cureus. 2023 Mar 7;15(3):e35880. doi: 10.7759/cureus.35880. eCollection 2023 Mar.
4
Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment.
Int J Mol Sci. 2022 Oct 24;23(21):12810. doi: 10.3390/ijms232112810.
5
Adult-onset Still's disease with concurrent acute necrotizing encephalopathy: a case report.
BMC Neurol. 2022 Sep 1;22(1):329. doi: 10.1186/s12883-022-02844-6.
6
Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.
Front Immunol. 2022 Aug 11;13:919973. doi: 10.3389/fimmu.2022.919973. eCollection 2022.
7
Cardiac Tamponade as a Rare Presentation of Adult-Onset Still's Disease.
Cureus. 2021 Dec 3;13(12):e20147. doi: 10.7759/cureus.20147. eCollection 2021 Dec.
8
Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab.
J Clin Med. 2021 Sep 26;10(19):4400. doi: 10.3390/jcm10194400.
9
An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.
J Immunol Res. 2021 Jun 20;2021:8998358. doi: 10.1155/2021/8998358. eCollection 2021.
10
The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still's Disease.
Genes (Basel). 2021 Jun 11;12(6):904. doi: 10.3390/genes12060904.
本文引用的文献
1
The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease.
Semin Arthritis Rheum. 2012 Oct;42(2):201-5. doi: 10.1016/j.semarthrit.2012.03.004. Epub 2012 Apr 17.
2
Neutrophil CD64 is upregulated in patients with active adult-onset Still's disease.
Scand J Rheumatol. 2012 Mar;41(2):156-8. doi: 10.3109/03009742.2011.644325.
3
Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.
Clin Rheumatol. 2012 May;31(5):853-60. doi: 10.1007/s10067-012-1952-1. Epub 2012 Feb 10.
4
Development and function of interleukin 17-producing γδ T cells.
Ann N Y Acad Sci. 2012 Jan;1247:34-45. doi: 10.1111/j.1749-6632.2011.06355.x. Epub 2012 Jan 12.
5
Th17 response and inflammatory autoimmune diseases.
Int J Inflam. 2012;2012:819467. doi: 10.1155/2012/819467. Epub 2011 Nov 15.
6
Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.
Clin Rheumatol. 2012 Mar;31(3):569-74. doi: 10.1007/s10067-011-1917-9. Epub 2012 Jan 4.
7
Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan.
Mod Rheumatol. 2012 Sep;22(5):712-9. doi: 10.1007/s10165-011-0569-6. Epub 2011 Dec 9.
8
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342.
9
Mycoplasma pneumoniae infection associated with urticarial vasculitis mimicking adult-onset Still's disease.
Rheumatol Int. 2012 Dec;32(12):4053-6. doi: 10.1007/s00296-011-2107-4. Epub 2011 Sep 15.
10
Refractory adult-onset still disease successfully treated with abatacept.
J Clin Rheumatol. 2011 Sep;17(6):315-7. doi: 10.1097/RHU.0b013e31822c53ad.
Zotero 插件